Expression of CD44 splicing isoforms in lung cancers: Dominant expression of CD44v8-10 in non-small cell lung carcinomas

J. I.Ichiro Sasaki, Kenneth K. Tanabe, Kazuhisa Takahashi, Isamu Okamoto, Hisao Fujimoto, Mitsuhiro Matsumoto, Moritaka Suga, Masayuki Ando, Hideyuki Saya

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

We examined CD44 isoform expression in 138 frozen tissue samples, which included primary lung carcinomas, adjacent non-tumorous lung tissues and benign lung diseases, by both reverse transcriptase polymerase chain reaction (RT-PCR) and immunohistochemical analyses. CD44v8-10 mRNA and protein were dominantly expressed in non-small cell lung carcinomas (NSCLC), while non-tumorous tissues principally expressed CD44s and small cell lung carcinomas (SCLC) expressed either CD44s or no detectable CD44. These results indicate that CD44v8-10 is the dominant splicing isoform in NSCLC and can be practically utilized as a diagnostic marker and therapeutical target in NSCLC.

Original languageEnglish
Pages (from-to)525-533
Number of pages9
JournalInternational journal of oncology
Volume12
Issue number3
DOIs
Publication statusPublished - 03-1998

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Expression of CD44 splicing isoforms in lung cancers: Dominant expression of CD44v8-10 in non-small cell lung carcinomas'. Together they form a unique fingerprint.

  • Cite this

    Sasaki, J. I. I., Tanabe, K. K., Takahashi, K., Okamoto, I., Fujimoto, H., Matsumoto, M., Suga, M., Ando, M., & Saya, H. (1998). Expression of CD44 splicing isoforms in lung cancers: Dominant expression of CD44v8-10 in non-small cell lung carcinomas. International journal of oncology, 12(3), 525-533. https://doi.org/10.3892/ijo.12.3.525